SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): May 6, 2008
Neuralstem,
Inc.
(Exact
name of registrant as specified in Charter)
|
Delaware
|
|
000-1357459
|
|
52-2007292
|
| |
|
|
|
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File No.)
|
|
(IRS
Employee Identification
No.)
|
9700
Great Seneca Highway, Rockville, Maryland 20850
(Address
of Principal Executive Offices)
(301)
366-4841
(Issuer
Telephone number)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On
May 6,
2008, Neuralstem, Inc. (the “Company”) issued a press release announcing they
filed a motion to re-open the infringement litigation with StemCells, Inc.
and
have the stay lifted in order to seek disposition on summary judgment grounds.
The following are attached as exhibits to this Current Report on Form 8-K:
(i) copy of press release, Exhibit 99.1; and (ii) copy of the motion to re-open
the infringement litigation, Exhibit 99.2.
The
information contained in this Current Report on Form 8-K and the exhibits
attached hereto shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall such information
or such exhibits be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The information
set
forth in or exhibits to this Form 8-K shall not be deemed an admission as to
the
materiality of any information in this report on Form 8-K that is required
to be
disclosed solely to satisfy the requirements of Regulation FD.
| Item
9.01 |
Financial
Statement and Exhibits.
|
|
Exhibit
Number
|
|
Description
|
|
|
|
| |
|
|
|
99.1
|
|
Press
Release Dated May 6, 2008
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report on Form 8-K to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
|
|
| |
NEURALSTEM,
INC
|
|
|
|
| |
By: |
/s/ I.
Richard Garr |
| |
I.
Richard Garr |
| |
Chief
Executive Officer
|
Dated:
May 6, 2008